Evolving technologies starting with tracer studies, and more recently with genomics and proteomics, have provided novel information about the molecular properties of cerebral endothelium and astrocytes; however, further studies must be done in animal models of neurological diseases and in humans to get a clearer understanding of the pathogenesis of blood-brain barrier (BBB) breakdown in nervous system diseases.